Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635 | Active Not Recruiting FDA Device

• 1 other identifier: 201-2022
• Study Type: interventional
• Target: 20,000
• Locations: 1 country
• Sites: 1

Brief Summary

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

Conditions

Weight Loss; Metabolic Syndrome; Diabetes Mellitus, Type 2; Central Obesity; Insulin Resistance; Glucose Intolerance; Metabolic Glucose Disorders

Keywords

health and wellness; excess adiposity

Outcome Measures

Primary Outcomes (3)

• Glucose Metrics via Continuous Glucose Measurement (CGM)

  Glucose measured in mg/dl

  During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

• Change in weight in pounds

  Change in number of pounds

  During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

• App engagement

  Meals logged, Exercises logged, Activities completed

  During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

Study Arms (1)

Signos digital health app and CGM

EXPERIMENTAL

For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.

Device: Continuous Glucose Monitor Device

Interventions

Continuous Glucose Monitor Device DEVICE

Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.

Also known as: CGM

Signos digital health app and CGM

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Medical diagnosis of Type 2 Diabetes; determined by review of subject-provided most recent Hg A1c.
• Subject is under current care of a primary care provider or specialist
• Clearance by medical provider to participate in diet, physical activity, and lifestyle changes
• years and above
• Own a smartphone and be willing to install the Signos App to personally receive text messages or have access to a web-based survey to self-report their weight.
• Willingness to complete quality of life questionnaires or other in-app surveys.
• Willingness to use CGM device
• Able to speak and read English
• Be a Signos mHealth (mobile/web-based) user

You may not qualify if:

• Medical diagnosis of Type 1 Diabetes
• Type 2 Diabetes currently using insulin or most recent A1c ≥10%
• Severe hypoglycemia \<54 mg/dl resulting in seizure or unconsciousness, or requiring assistance/EMS/hospitalization - within 3 months prior to enrollment
• Current medical diagnosis of an eating disorder (such as anorexia nervosa or bulimia)
• Medical conditions (e.g., such as seizure disorder) requiring a specific medical diet.
• Inborn error of metabolism such as phenylketonuria (PKU), glycogen storage disease, fructose intolerance, Maple Sugar Urine Disease (MSUD).
• History of 10 or more soft tissue skin infections (such as cellulitis or abscesses)
• Intolerable skin reaction from adhesive
• Currently taking any of the following medications: Clozapine, Hydroxyurea, or any form of insulin.

Sponsors & Collaborators

• Signos Inc: lead

Study Sites (1)

Signos

Palo Alto, California, 94306, United States

Location

Related Publications (14)

• Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018 Jul 24;16(7):e2005143. doi: 10.1371/journal.pbio.2005143. eCollection 2018 Jul.

  PMID: 30040822 RESULT

• Adams OP. The impact of brief high-intensity exercise on blood glucose levels. Diabetes Metab Syndr Obes. 2013;6:113-22. doi: 10.2147/DMSO.S29222. Epub 2013 Feb 27.

  PMID: 23467903 RESULT

• Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.

  PMID: 26590418 RESULT

• Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol. 2001 Sep 20;88(6A):16H-9H. doi: 10.1016/s0002-9149(01)01832-x.

  PMID: 11576521 RESULT

• Brown A, McArdle P, Taplin J, Unwin D, Unwin J, Deakin T, Wheatley S, Murdoch C, Malhotra A, Mellor D. Dietary strategies for remission of type 2 diabetes: A narrative review. J Hum Nutr Diet. 2022 Feb;35(1):165-178. doi: 10.1111/jhn.12938. Epub 2021 Sep 1.

  PMID: 34323335 RESULT

• Chin SO, Keum C, Woo J, Park J, Choi HJ, Woo JT, Rhee SY. Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. Sci Rep. 2016 Nov 7;6:34563. doi: 10.1038/srep34563.

  PMID: 27819345 RESULT

• Ebbeling CB, Knapp A, Johnson A, Wong JMW, Greco KF, Ma C, Mora S, Ludwig DS. Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial. Am J Clin Nutr. 2022 Jan 11;115(1):154-162. doi: 10.1093/ajcn/nqab287. Erratum In: Am J Clin Nutr. 2022 Jan 11;115(1):310. doi: 10.1093/ajcn/nqab372.

  PMID: 34582545 RESULT

• Ehrhardt N, Al Zaghal E. Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring. J Diabetes Sci Technol. 2019 Mar;13(2):271-275. doi: 10.1177/1932296818790994. Epub 2018 Aug 1.

  PMID: 30066574 RESULT

• The Lancet Diabetes Endocrinology. Metabolic health: a priority for the post-pandemic era. Lancet Diabetes Endocrinol. 2021 Apr;9(4):189. doi: 10.1016/S2213-8587(21)00058-9. Epub 2021 Mar 4. No abstract available.

  PMID: 33676599 RESULT

• Galderisi A, Giannini C, Weiss R, Kim G, Shabanova V, Santoro N, Pierpont B, Savoye M, Caprio S. Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis. Lancet Child Adolesc Health. 2018 Oct;2(10):726-735. doi: 10.1016/S2352-4642(18)30235-9. Epub 2018 Aug 24.

  PMID: 30236381 RESULT

• Gonzalez-Rodriguez M, Pazos-Couselo M, Garcia-Lopez JM, Rodriguez-Segade S, Rodriguez-Garcia J, Tunez-Bastida C, Gude F. Postprandial glycemic response in a non-diabetic adult population: the effect of nutrients is different between men and women. Nutr Metab (Lond). 2019 Jul 17;16:46. doi: 10.1186/s12986-019-0368-1. eCollection 2019.

  PMID: 31346341 RESULT

• Guyenet SJ, Schwartz MW. Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab. 2012 Mar;97(3):745-55. doi: 10.1210/jc.2011-2525. Epub 2012 Jan 11.

  PMID: 22238401 RESULT

• Hamley S, Kloosterman D, Duthie T, Dalla Man C, Visentin R, Mason SA, Ang T, Selathurai A, Kaur G, Morales-Scholz MG, Howlett KF, Kowalski GM, Shaw CS, Bruce CR. Mechanisms of hyperinsulinaemia in apparently healthy non-obese young adults: role of insulin secretion, clearance and action and associations with plasma amino acids. Diabetologia. 2019 Dec;62(12):2310-2324. doi: 10.1007/s00125-019-04990-y. Epub 2019 Sep 6.

  PMID: 31489455 RESULT

• Hyde PN, Sapper TN, Crabtree CD, LaFountain RA, Bowling ML, Buga A, Fell B, McSwiney FT, Dickerson RM, Miller VJ, Scandling D, Simonetti OP, Phinney SD, Kraemer WJ, King SA, Krauss RM, Volek JS. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight. 2019 Jun 20;4(12):e128308. doi: 10.1172/jci.insight.128308. eCollection 2019 Jun 20.

  PMID: 31217353 RESULT

MeSH Terms

Conditions

Weight Loss; Metabolic Syndrome; Diabetes Mellitus, Type 2; Obesity, Abdominal; Insulin Resistance; Glucose Intolerance; Glucose Metabolism Disorders

Condition Hierarchy (Ancestors)

Body Weight Changes; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism; Metabolic Diseases; Nutritional and Metabolic Diseases; Diabetes Mellitus; Endocrine System Diseases; Obesity; Overweight; Overnutrition; Nutrition Disorders; Hyperglycemia

Study Officials

• Stephanie Kim, MD

  Signos Inc

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Open label single-arm study

Study Record Dates

• First Submitted: May 16, 2023
• First Posted: May 25, 2023
• Study Start: May 11, 2023
• Primary Completion (Estimated): May 10, 2028
• Study Completion (Estimated): May 10, 2029
• Last Updated: August 29, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)